Chemical Structure (Cimetidine Os 1)
Cimetidine Hydrochloride Solution
Product Images NDC 0121-1025
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Cimetidine Hydrochloride (NDC 0121-1025). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Pai Holdings, Llc Dba Pai Pharma, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Table1 (Cimetidine Os 2)
This appears to be a table listing different stimulants and their percentages of inhibition at certain doses and time intervals. It includes information on drugs like Betazole, Pentagastrin, Cimetidine, Caffeine, and Insulin, along with their doses and respective inhibition percentages.*
Table 2 (Cimetidine Os 3)
This text provides data on duodenal ulcer healing rates based on different oral cimetidine dosage regimens. Healing rates at weeks 4, 6, and 8 are presented for cimetidine dosages of 300mg, 400mg, 800mg, and 1600mg given at various frequencies (q.i.d., b.i.d., h.s.). These percentages reflect averages from controlled clinical trials.*
Table 3 (Cimetidine Os 4)
This text contains data from a study comparing the healing rates of cimetidine and a placebo for gastrointestinal issues. The results include percentages of patients healed at week 2 and week 6 for both cimetidine and placebo. There are also mentions of statistical significance with p-values indicated. The study is mentioned to be multicenter and involved an 800 mg oral regimen of cimetidine.*
Table 4 (Cimetidine Os 5)
This text describes the results of a study comparing the effects of cimetidine and a placebo on certain parameters. It includes data on the percentage of individuals showing certain outcomes at different time points for both treatments. The results indicate a statistically significant difference between the cimetidine and placebo groups.*
Cimetidine Hydrochloride Oral Solution (Cimetidine Os 6)
This text is about an oral solution of Cimetidine Hydrochloride distributed by PAI Pharma. The solution contains 300 mg/5 mL of Cimetidine and is to be dispensed in a tight, light-resistant container. The packaging also emphasizes the need for safety closures when dispensing the product and recommends storage at temperatures of 20° to 25°C (68° to 77°F). Additional information such as NDC number and usual dosage guidelines are also provided. For more detailed dosage instructions and prescribing information, the package insert should be consulted.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
